IGF2 and Alzheimer disease: qRT-PCR analysis and western blotting revealed that the gene and protein expression of Igf2 was markedly decreased in mouse primary BMSCs treated with antagomiR-NC-pretreated AD-B-EVs, and was partially recovered by antagomiR-483-5p-pretreated AD-B-EVs (Figure 7A-C), indicating that the blockade of miR-483-5p abolishes the inhibitory effect of AD-B-EVs on Igf2 expression.